ArticleLung2014
Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients.
Article in Lung, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms.Frontiers in immunology · 2018Pooled it
- Effects of Low-Dose and Long-Term Treatment with Erythromycin on Interleukin-17 and Interleukin-23 in Peripheral Blood and Induced Sputum in Patients with Stable Chronic Obstructive Pulmonary Disease.Mediators of inflammation · 2016Trial
- Inflammatory Phenotypes of Bronchiectasis.Journal of personalized medicine · 2025Review
- Challenges and Opportunities for Post-COVID Pulmonary Disease: A Focused Review of Immunomodulation.International journal of molecular sciences · 2025Review
- The role of T-helper and T regulatory cells in driving neutrophilic and eosinophilic inflammation in bronchiectasis.Frontiers in immunology · 2025Review
- The Airway Microbiome-IL-17 Axis: a Critical Regulator of Chronic Inflammatory Disease.Clinical reviews in allergy & immunology · 2023Review
- Immunomodulatory Effects of Macrolides Considering Evidence from Human and Veterinary Medicine.Microorganisms · 2022Review
- The clinical phenotype of bronchiectasis and its clinical guiding implications.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact ofJournal of clinical medicine · 2020Article
- Possible mechanisms of action of clarithromycin and its clinical application as a repurposing drug for treating multiple myeloma.Ecancermedicalscience · 2020Review
- Erythromycin Suppresses the Cigarette Smoke Extract-Exposed Dendritic Cell-Mediated Polarization of CD4Journal of immunology research · 2020Article
- Challenges of diagnosing and managing bronchiectasis in resource-limited settings: a case study.The Pan African medical journal · 2019Article
- Louqin Zhisou Decoction Inhibits Mucus Hypersecretion for Acute Exacerbation of Chronic Obstructive Pulmonary Disease Rats by Suppressing EGFR-PI3K-AKT Signaling Pathway and Restoring Th17/Treg Balance.Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Efficacy of clarithromycin as a protective agent in the methotrexate-induced pulmonary fibrosis model.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2018Article
- Adult non-cystic fibrosis bronchiectasis is characterised by airway luminal Th17 pathway activation.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTh17 cells play a crucial role in neutrophilic inflammation and tissue injury in non-cystic fibrosis (non-CF) bronchiectasis. Clarithromycin demonstrates anti-inflammatory and immunomodulatory properties but the effect of long-term clarithromycin prophylaxis on the Th17 response in non-CF bronchiectasis is still unexplored.
methodsTh17 response was studied in 22 patients with stable non-CF bronchiectasis receiving daily 500-mg clarithromycin for 12 weeks. We analysed IL-17 concentrations in exhaled breath condensate (EBC) and peripheral blood Th17 cells, whereas functional parameters and clinical data were recorded in parallel.
resultsBoth, post-treatment absolute counts of CD4+IL17+ cells in peripheral blood and IL-17 levels in EBC decreased significantly (post-treatment CD4+IL17+ mean 2.418 ± 0.414 cells/μl versus pre-treatment 3.202 ± 0.507 cells/μl, p = 0.036 and post-treatment IL-17 mean levels 7.16 ± 0.47 pg/ml versus pre-treatment 9.32 ± 0.47 pg/ml, p < 0.001, respectively). Post-treatment EBC IL-17 levels decreased significantly in both patients who exhibited exacerbations and those who remained stable during the study period (mean 6.72 ± 0.37 versus 9.12 ± 0.64 pg/ml, p = 0.01 and 7.69 ± 0.9 versus 9.53 ± 0.72 pg/ml, p = 0.042, respectively), while pre-treatment and post-treatment levels did not differ between the two groups (p = 0.665 and p = 0.465, respectively). PaO(2) improved significantly (post-treatment mean 77.73 ± 2.23 mmHg versus pre-treatment 73.18 ± 2.22 mmHg, p = 0.025), while PaCO(2), post-bronchodilation FEV1, and post-bronchodilation FVC remained unaltered.
conclusionsOur results argue for a reduction of both systemic and local Th17 response after prophylactic, low-dose clarithromycin administration in patients with non-CF bronchiectasis, suggestive of a potential anti-inflammatory and/or immunomodulatory action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.